The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer's Disease Who Are Currently Treated With Lecanemab.

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 1, 2025

Primary Completion Date

April 1, 2028

Study Completion Date

December 30, 2028

Conditions

Alzheimers Disease

Interventions

DRUG

X/T + X-EC

Xanomeline and Trospium Chloride Capsules

DRUG

Placebo

DRUG

Lecanemab 10 mg/kg

Participants will continue their current Lecanemab infusions while in the study receiving the study drug or placebo.